These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 10762127)
21. The impact of treatment with levodopa on Parkinson's disease. Shaw KM; Lees AJ; Stern GM Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763 [TBL] [Abstract][Full Text] [Related]
22. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135 [TBL] [Abstract][Full Text] [Related]
24. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
25. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F; Lilliu H; Le Pen C Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770 [TBL] [Abstract][Full Text] [Related]
26. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Manson AJ; Turner K; Lees AJ Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062 [TBL] [Abstract][Full Text] [Related]
27. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Nutt JG Mov Disord; 2007 Jan; 22(1):1-9. PubMed ID: 16958130 [TBL] [Abstract][Full Text] [Related]
28. Molecular basis of levodopa-induced dyskinesias. Calon F; Grondin R; Morissette M; Goulet M; Blanchet PJ; Di Paolo T; Bédard PJ Ann Neurol; 2000 Apr; 47(4 Suppl 1):S70-8. PubMed ID: 10762134 [TBL] [Abstract][Full Text] [Related]
29. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches. Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656 [TBL] [Abstract][Full Text] [Related]
30. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186 [TBL] [Abstract][Full Text] [Related]
31. [Variance in effects of subthalamic nucleus stimulation]. Okiyama R; Yokochi F; Taniguchi M; Takahashi H; Hasegawa N; Hamada I No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577 [TBL] [Abstract][Full Text] [Related]
32. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]